Subject: FW: Client OTC derivatives trading with CIB [I] From: Funda Bozkurt ‹ > Date: Fri, 15 Feb 2019 17:33:04 -0500 To: Ian Salters Thomas Klemm Cc: Kimberly Hart Classification: For internal use only Ian, I received your email around the Opt up process in PDFs. It is quite helpful. May I see the desk's KOPs and Ellenoi's/Nina's procedures? It should not be a separate process, but the new process should be inserted to WM GM procedures. Please attach the action plan to the SII in DBtrack and call me if you have any further questions or even a help with attaching the doc. We need to closely monitor the remediation and provide updates to the action plan. As I glance through your list, I am not clear on a couple of things, please clarify what the total population is, how did you determine the priority what happens to the clients that are not being prioritized or will not be on boarded onto GM. Did off boarding process start? We are not delivering the WM KYC docs to GM anymore? I thought we were going to ask for the deltas. If not, please clarify the onboarding process as this is not how WM is onboarding the clients. KOP language Also, I have been asking for a while, but GM and WM should have an SLA in place that outlines the roles and responsibilities. I have more but let's meet once you are back. Thanks and have a great time off. PS. I am very surprised to hear that this is the first time you are hearing abt this as Kim and I have been asking for the plan for a while now. Funda Bozkurt Deutsche Bank Trust Company Americas. WM-Divisional Control Office 345 Park Avenue, 10154-0004 New York, NY, USA Tel. Email EFTA01399171